Weight-Loss drug plus IUD aimed to save uteruses – but trial never started
NCT ID NCT05829460
First seen Jan 12, 2026 · Last updated Jun 20, 2026 · Updated 17 times
Summary
This study planned to test whether combining semaglutide (a weight-loss drug) with a hormone-releasing IUD could help premenopausal women with obesity and endometrial hyperplasia avoid hysterectomy. The goal was to reverse the precancerous condition and preserve the uterus. However, the trial was withdrawn before enrolling anyone, so no data were collected.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIAL HYPERPLASIA are added.
Genom att skicka in godkänner du våra Användarvillkor
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Semaglutide (a GLP-1 receptor agonist) and a levonorgestrel-releasing intrauterine device (LNG-IUD)
What this could lead to
If it had worked, this combination could have offered a non-surgical way to preserve the uterus and manage endometrial hyperplasia in premenopausal women with obesity.
What could go wrong
The trial was withdrawn before enrolling any participants, so no results are available. The approach remains untested in this specific population.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.